GSK PLC Sponsored ADR $GSK Stock Acquired by Kestra Advisory Services LLC

Kestra Advisory Services LLC lifted its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 9.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 186,862 shares of the pharmaceutical company’s stock after purchasing an additional 16,031 shares during the period. Kestra Advisory Services LLC’s holdings in GSK were worth $9,001,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GSK. Optimist Retirement Group LLC grew its stake in shares of GSK by 2.5% during the 3rd quarter. Optimist Retirement Group LLC now owns 52,316 shares of the pharmaceutical company’s stock worth $2,520,000 after acquiring an additional 1,276 shares during the period. Pzena Investment Management LLC boosted its holdings in shares of GSK by 18.2% in the third quarter. Pzena Investment Management LLC now owns 28,964 shares of the pharmaceutical company’s stock worth $1,395,000 after acquiring an additional 4,457 shares during the period. Provenance Wealth Advisors LLC grew its position in shares of GSK by 378.8% in the third quarter. Provenance Wealth Advisors LLC now owns 1,149 shares of the pharmaceutical company’s stock valued at $55,000 after purchasing an additional 909 shares in the last quarter. Integrity Alliance LLC. bought a new stake in shares of GSK during the 3rd quarter valued at $221,000. Finally, GRIMES & Co WEALTH MANAGEMENT LLC lifted its holdings in GSK by 2.3% during the 3rd quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 186,887 shares of the pharmaceutical company’s stock worth $9,002,000 after purchasing an additional 4,142 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GSK. HSBC reaffirmed a “hold” rating on shares of GSK in a research note on Thursday, September 10th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their price target for the company from $67.40 to $55.90 in a report on Thursday, October 29th. Morgan Stanley reissued an “underweight” rating on shares of GSK in a report on Tuesday, August 25th. Barclays reissued a “sell” rating on shares of GSK in a research note on Monday, September 7th. Finally, Deutsche Bank Aktiengesellschaft restated a “neutral” rating on shares of GSK in a research report on Tuesday, September 29th. Three equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, GSK currently has a consensus rating of “Hold” and an average price target of $56.30.

GSK Trading Down 0.5%

NYSE GSK opened at $51.27 on Wednesday. The stock has a 50-day moving average of $49.30 and a 200-day moving average of $52.39. The company has a current ratio of 0.86, a quick ratio of 0.56 and a debt-to-equity ratio of 1.18. GSK PLC Sponsored ADR has a 1-year low of $45.81 and a 1-year high of $61.69. The firm has a market cap of $103.70 billion, a PE ratio of 17.81, a price-to-earnings-growth ratio of 2.32 and a beta of 0.28.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Friday, November 13th will be issued a dividend of $0.4518 per share. The ex-dividend date is Friday, November 13th. This represents a $1.81 dividend on an annualized basis and a yield of 3.5%. This is an increase from GSK’s previous quarterly dividend of $0.4515. GSK’s dividend payout ratio (DPR) is currently 61.46%.

GSK Profile

GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.